Journal
JOURNAL OF IMMUNOLOGY
Volume 198, Issue 4, Pages 1439-1451Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.1601702
Keywords
-
Categories
Funding
- Drug Development Institute at The Ohio State University Comprehensive Cancer Center
- National Institutes of Health National Institute of Allergy and Infectious Diseases [R01AI121405, 1R21AI127354]
- Leukemia Lymphoma Society Translational Research Program
- Ohio State University School of Health and Rehabilitation Sciences
- National Institutes of Health [IHAI111125CA100730]
- Comprehensive Cancer Center Medicinal Chemistry Shared Resource [P30CA016058]
Ask authors/readers for more resources
In the autoimmune disease multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis (EAE), expansion of pathogenic, myelin-specific Th1 cell populations drives active disease; selectively targeting this process may be the basis for a new therapeutic approach. Previous studies have hinted at a role for protein arginine methylation in immune responses, including T cell-mediated autoimmunity and EAE. However, a conclusive role for the protein arginine methyltransferase (PRMT) enzymes that catalyze these reactions has been lacking. PRMT5 is the main PRMT responsible for symmetric dimethylation of arginine residues of histones and other proteins. PRMT5 drives embryonic development and cancer, but its role in T cells, if any, has not been investigated. In this article, we show that PRMT5 is an important modulator of CD4(+) T cell expansion. PRMT5 was transiently upregulated during maximal proliferation of mouse and human memory Th cells. PRMT5 expression was regulated upstream by the NF-kappa B pathway, and it promoted IL-2 production and proliferation. Blocking PRMT5 with novel, highly selective small molecule PRMT5 inhibitors severely blunted memory Th expansion, with preferential suppression of Th1 cells over Th2 cells. In vivo, PRMT5 blockade efficiently suppressed recall T cell responses and reduced inflammation in delayed-type hypersensitivity and clinical disease in EAE mouse models. These data implicate PRMT5 in the regulation of adaptive memory Th cell responses and suggest that PRMT5 inhibitors may be a novel therapeutic approach for T cell-mediated inflammatory disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available